Literature DB >> 21862934

Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study.

Zhao Cui1, Juan Zhao, Xiao-Yu Jia, Sai-Nan Zhu, Qi-Zhuang Jin, Xu-Yang Cheng, Ming-Hui Zhao.   

Abstract

Anti-glomerular basement membrane (GBM) disease usually presents with rapidly progressive glomerulonephritis accompanied by pulmonary hemorrhage. The low incidence and fulminant course of disease preclude a large randomized controlled study to define the benefits of any given therapy. We conducted a retrospective survey of 221 consecutive patients seen from 1998 to 2008 in our hospital, and report here the patient and renal survival and the risk factors affecting the outcomes. Considering the similar clinical features of the patients, we could compare the effects of 3 different treatment regimens: 1) combination therapy of plasmapheresis and immunosuppression, 2) steroids and cytotoxic agents, and 3) steroids alone.The patient and renal survival rates were 72.7% and 25.0%, respectively, at 1 year after disease presentation. The serum level of anti-GBM antibodies (increased by 20 U/mL; hazard ratio [HR], 1.16; p = 0.009) and the presentation of positive antineutrophil cytoplasmic antibodies (ANCA) (HR, 2.18; p = 0.028) were independent predictors for patient death. The serum creatinine at presentation (doubling from 1.5 mg/dL; HR, 2.07; p < 0.001) was an independent predictor for renal failure.The combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide had an overall beneficial effect on both patient survival (HR for patient mortality, 0.31; p = 0.001) and renal survival (HR for renal failure, 0.60; p = 0.032), particularly patient survival for those with Goodpasture syndrome (HR for patient mortality, 0.29; p = 0.004) and renal survival for those with anti-GBM nephritis with initial serum creatinine over 6.8 mg/dL (HR for renal failure, 0.52; p = 0.014). The treatment with corticosteroids plus cyclophosphamide was found not to improve the renal outcome of disease (p = 0.73). In conclusion, the combination therapy was preferred for patients with anti-GBM disease, especially those with pulmonary hemorrhage or severe renal damage. Early diagnosis was crucial to improving outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862934     DOI: 10.1097/MD.0b013e31822f6f68

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  26 in total

Review 1.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

2.  AP-VAS 2012 case report: anti-glomerular basement membrane disease with high titer of myeloperoxidase anti-neutrophil cytoplasmic antibody-an autopsy case report.

Authors:  Miho Otani; Hiroki Shoji; Hiromi Tomioka; Toshihiko Kaneda; Yoko Kida; Masahiro Kaneko; Hiroshi Fujii; Yoshihiko Nakajima; Eiji Katsuyama
Journal:  CEN Case Rep       Date:  2013-04-10

3.  Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life.

Authors:  Marina Sánchez-Agesta; Cristina Rabasco; María J Soler; Amir Shabaka; Elisabeth Canllavi; Saulo J Fernández; Juan M Cazorla; Esperanza López-Rubio; Ana Romera; Sergio Barroso; Ana Huerta; Leonardo Calle; Milagros Sierra; Patricia Domínguez-Torres; Manuela Moreno-Ramírez; Sara Afonso; Victoria Mascarós; Armando Coca; Mario Espinosa
Journal:  Front Med (Lausanne)       Date:  2022-07-05

Review 4.  Goodpasture's autoimmune disease - A collagen IV disorder.

Authors:  Vadim Pedchenko; A Richard Kitching; Billy G Hudson
Journal:  Matrix Biol       Date:  2018-05-12       Impact factor: 11.583

5.  Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

Authors:  Emma E van Daalen; J Charles Jennette; Stephen P McAdoo; Charles D Pusey; Marco A Alba; Caroline J Poulton; Ron Wolterbeek; Tri Q Nguyen; Roel Goldschmeding; Bassam Alchi; Meryl Griffiths; Janak R de Zoysa; Beula Vincent; Jan A Bruijn; Ingeborg M Bajema
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-21       Impact factor: 8.237

6.  What is new in the management of rapidly progressive glomerulonephritis?

Authors:  George H B Greenhall; Alan D Salama
Journal:  Clin Kidney J       Date:  2015-02-19

7.  Anti-glomerular basement membrane crescentic glomerulonephritis: A report from India and review of literature.

Authors:  A Gupta; V Agrawal; A Kaul; R Verma; R Pandey
Journal:  Indian J Nephrol       Date:  2016-09

8.  Rescue of kidney function in a toddler with anti-GBM nephritis.

Authors:  Anna Bjerre; Kolbjørn Høgåsen; Jon Grøtta; Helge Scott; Trine Tangeraas; Christina Dörje
Journal:  Clin Kidney J       Date:  2012-12

9.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.

Authors:  Peter Biesenbach; Renate Kain; Kurt Derfler; Thomas Perkmann; Afschin Soleiman; Alexandra Benharkou; Wilfred Druml; Andrew Rees; Marcus D Säemann
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

Review 10.  Anti-Glomerular Basement Membrane Disease.

Authors:  Stephen P McAdoo; Charles D Pusey
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.